These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Brain imaging in cerebellar ataxia associated with autoimmune polyglandular syndrome type 2. Manto M; Jissendi P J Neuroimaging; 2012 Jul; 22(3):308-11. PubMed ID: 21091821 [TBL] [Abstract][Full Text] [Related]
6. Cerebellar degeneration and polyglandular autoimmune syndrome with anti-glutamic acid decarboxylase antibodies. Rüegg S; Stahl M; Bühlmann M; Dupont A; Lyrer PA; Humbel RL; Steck AJ J Neurol; 2002 Mar; 249(3):348-50. PubMed ID: 11993540 [No Abstract] [Full Text] [Related]
7. Bilateral anterior granulomatous keratouveitis with sunset glow fundus in a patient with autoimmune polyglandular syndrome. Futagami Y; Sugita S; Fujimaki T; Yokoyama T; Morio T; Mochizuki M Ocul Immunol Inflamm; 2009; 17(2):88-90. PubMed ID: 19412868 [TBL] [Abstract][Full Text] [Related]
8. Organospecific lymph node enlargement in autoimmune polyglandular syndrome. Hummel M; Banholzer P; Rabl W; Ziegler AG Diabetes Care; 1998 Sep; 21(9):1573-4. PubMed ID: 9727916 [No Abstract] [Full Text] [Related]
9. Auto-immune cerebellar ataxia with anti-GAD antibodies accompanied by de novo late-onset type 1 diabetes mellitus. Bayreuther C; Hieronimus S; Ferrari P; Thomas P; Lebrun C Diabetes Metab; 2008 Sep; 34(4 Pt 1):386-8. PubMed ID: 18583169 [TBL] [Abstract][Full Text] [Related]
10. Time to insulin initiation cannot be used in defining latent autoimmune diabetes in adults. Brophy S; Yderstraede K; Mauricio D; Hunter S; Hawa M; Pozzilli P; Schernthaner G; Schloot N; Buzzetti R; Davies H; Leslie D; Williams R; Diabetes Care; 2008 Mar; 31(3):439-41. PubMed ID: 18083788 [TBL] [Abstract][Full Text] [Related]
11. [When and why should anti-GAD antibodies by looked for in the non-insulin-dependent diabetic patient?]. Atlan-Gepner C; Vialettes B Diabetes Metab; 1999 Jun; 25(2):177-9. PubMed ID: 10443330 [No Abstract] [Full Text] [Related]
12. Frequency of diabetes and thyroid autoantibodies in patients with autoimmune endocrine disease from Cameroon. Hawa MI; Picardi A; Costanza F; D'Avola D; Beretta Anguissola G; Guglielmi C; Mottini G; Fezeu L; Mbanya JC; Leslie RD; Pozzilli P Clin Immunol; 2006; 118(2-3):229-32. PubMed ID: 16298164 [TBL] [Abstract][Full Text] [Related]
13. Autoimmune polyglandular syndrome type 3 variant in rheumatoid arthritis. Horino T; Ogasawara M; Ichii O; Terada Y Rom J Intern Med; 2020 Mar; 58(1):40-43. PubMed ID: 31756165 [TBL] [Abstract][Full Text] [Related]
14. Glutamic acid decarboxylase autoantibodies and neurological disorders. Vianello M; Tavolato B; Giometto B Neurol Sci; 2002 Oct; 23(4):145-51. PubMed ID: 12536283 [TBL] [Abstract][Full Text] [Related]
15. Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital. Römkens TE; Kusters GC; Netea MG; Netten PM Neth J Med; 2006 Apr; 64(4):114-8. PubMed ID: 16609158 [TBL] [Abstract][Full Text] [Related]
16. Prevalence of Type 1 diabetes autoantibodies (GAD and IA2) in Sardinian children and adolescents with autoimmune thyroiditis. Pilia S; Casini MR; Cambuli VM; Ibba A; Civolani P; Zavattari P; Incani M; Mossa P; Baroni MG; Mariotti S; Loche S Diabet Med; 2011 Aug; 28(8):896-9. PubMed ID: 21749442 [TBL] [Abstract][Full Text] [Related]